Entering text into the input field will update the search result below

AbbVie: A 4% SWAN Stock

Mar. 14, 2023 10:31 AM ETAbbVie Inc. (ABBV)10 Comments
Tradevestor profile picture


  • AbbVie is down about 8% YTD and appears undervalued at 13 times earnings.
  • Dividend coverage looks strong based on both Free Cash Flow and Earnings Per Share.
  • 4% yield combined with a low beta make this the perfect SWAN stock.

AbbVie headquarters building facade of an American publicly traded biopharmaceutical company

Michael Vi

AbbVie Inc. (NYSE:ABBV) has been my third largest healthcare holding behind Johnson & Johnson (JNJ) and Pfizer (PFE) for a while and it has been a terrific albeit under-rated performer for me. Although the


ABBV DG (Author, with data from Seeking Alpha)


ABBV Debt (YCharts.com)

ABBV Cash On Hand

ABBV Cash On Hand (YCharts.com)

ABBV Moving Avgs

ABBV Moving Avgs (Barchart.com)


ABBV RSI (Stockrsi.com)

This article was written by

Tradevestor profile picture
Dividends (DGI and DRIP) and Growth at reasonable price (GARP) for Long-term. Serious money.Fun trading for short-term. Play money.Ideas and thoughts presented in the articles are not professional recommendations.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV, MO, PM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.